Alkermes plc. Contract with Customer, Asset, after Allowance for Credit Loss, Current
Alkermes plc. (ALKS) had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2026-02-25
- 2025-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $0.00.
- 2025-09-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $717.00K.
- 2025-06-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $1.42M.
- 2025-03-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $3.05M.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2025-09-30 | $717.00K 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.42M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $3.05M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $4.99M 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.97M 10-Q · filed 2024-10-24 |
| 2024-06-30 | $3.49M 10-Q · filed 2024-07-24 |
| 2024-03-31 | $1.23M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $706.00K 10-K · filed 2025-02-12 |
| 2023-09-30 | $2.77M 10-Q · filed 2023-10-25 |
| 2023-03-31 | $8.43M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $8.93M 10-K · filed 2024-02-21 |
| 2022-09-30 | $10.11M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $16.49M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $20.21M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $13.36M 10-K · filed 2023-02-16 |
| 2021-09-30 | $3.51M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $8.79M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $9.28M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $14.40M 10-K · filed 2022-02-16 |
| 2020-09-30 | $14.39M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $9.24M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $14.20M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $8.39M 10-K · filed 2021-02-11 |
| 2019-09-30 | $5.02M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $12.69M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $8.45M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $8.23M 10-K · filed 2020-02-13 |
| 2018-09-30 | $13.48M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $14.58M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $26.07M 10-Q · filed 2018-04-26 |
| 2018-01-02 | $9.11M 10-Q · filed 2018-07-26 |
| 2018-01-01 | $9.11M 10-K · filed 2019-02-15 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |